• BioCardia flagged an upcoming HFSA 2026 poster detailing the design of its CardiAMP HF II heart-failure trial.
• Results have not been presented; the poster is scheduled for the October 9–12 meeting in Phoenix.
• The study is testing a high-dose autologous cell therapy in ischemic HFrEF patients still showing elevated heart-stress biomarkers on standard care.
• FDA has signaled the ongoing trial could be sufficient to support a potential US approval, sharpening the program’s regulatory path.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070900PRIMZONEFULLFEED9841218) on October 07, 2026, and is solely responsible for the information contained therein.